Biotech · Private company · Boston, MA, US
Imbria Pharmaceuticals, Inc.
SEC CIK 0001745672
Track this companyFree. Adds Imbria Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- IMB-1018972Phase 2 · Non-obstructive Hypertrophic CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
- IMB-1018972Phase 2 · Refractory AnginaClinicalTrials.gov · fetched Nov 12, 2026
- Ninerafaxstat 200mg MRPhase 2 · Non-obstructive Hypertrophic CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic CardiomyopathyPHASE2 · RECRUITING · started Oct 6, 2025ClinicalTrials.gov NCT07023614 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy TrialPHASE2 · COMPLETED · started Jun 14, 2021ClinicalTrials.gov NCT04826185 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory AnginaPHASE2 · WITHDRAWN · started May 1, 2020ClinicalTrials.gov NCT04306237 · fetched Nov 12, 2026